Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + letrozole first-line study in postmenopausal ER-positive metastatic breast cancer
NL-OMON41506Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus, letrozole, exemestane and dexamethasone in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Progression-free survival in the first-line setting. Started Jun 2014; status: active, not recruiting.
02
Drugs
everolimusletrozoleexemestanedexamethasone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON41506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41506.